Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)
Phase 2
Recruiting
- Registration Number
- CTRI/2007/091/000039
- Lead Sponsor
- The pharmaceutical company sponsoring this study is Bristol-MyersSquibb
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Documented NSCLC or SCLC
ECOG of 0 or 1
Exclusion Criteria
�� Brain metastases
�� Autoimmune disease
�� Known HIV, Hep B or Hep C infection
�� Peripheral neuropathy ≥ grade 2
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary Outcome Measures:<br>EORTC-QLQ-30 questionnaire [ Time Frame: completed at every<br>visit ]Timepoint: [ Time Frame: completed at every<br>visit ]
- Secondary Outcome Measures
Name Time Method Safety evaluations in all study armsTimepoint: At defined timepoints per the protocol